These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10952595)

  • 1. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.
    Furneri PM; Fresta M; Puglisi G; Tempera G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2458-64. PubMed ID: 10952595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
    Houston AK; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections.
    Galhano J; Marcelo GA; Duarte MP; Oliveira E
    Bioorg Chem; 2022 Jan; 118():105470. PubMed ID: 34814085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M; Wiedemann B
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.
    Fuchs PC; Jones RN; Barry AL; Gavan TL
    J Clin Microbiol; 1989 Jan; 27(1):49-52. PubMed ID: 2492304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation rates to 4-quinolone resistance.
    Smith JT
    Arzneimittelforschung; 1990 Jan; 40(1):65-8. PubMed ID: 2111135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa.
    Smith RP; Baltch AL; Franke MA; Michelsen PB; Bopp LH
    J Antimicrob Chemother; 2000 Apr; 45(4):483-8. PubMed ID: 10747825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-inhibitory and post-antibiotic effects of an optically active isomer of ofloxacin.
    Tanaka M; Une T; Osada Y
    Arzneimittelforschung; 1989 Jul; 39(7):750-4. PubMed ID: 2506868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.
    Barry A; Fuchs P; Tenover F; Allen S; Hardy D; Jorgensen J; McLaughlin J; Reller L
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):822-6. PubMed ID: 7889952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofloxacin, a bactericidal antibacterial.
    Smith JT
    Chemotherapy; 1991; 37 Suppl 1():2-13. PubMed ID: 1646700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
    Denis A; Moreau NJ
    J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis.
    Lewin CS; Morrissey I; Smith JT
    J Pharm Pharmacol; 1991 Jul; 43(7):492-4. PubMed ID: 1682462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibacterial activity of ofloxacin in urine for 4 days after a single oral dose of 400 mg].
    Guibert J; Kitzis MD; Acar JF
    Pathol Biol (Paris); 1998 Oct; 46(8):656-60. PubMed ID: 9871938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
    Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
    Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.